NDA 020899 · Ge Healthcare
Optison
Albumin Human · Injection · Contrast Agent for Ultrasound Imaging
Last checked: Nov 20, 2026Latest source record: May 9, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1997
Dec 31, 1997
Approved uses
3
Original approval plus efficacy supplements
Registered trials
477
95 Phase 3, 51 recruiting
FAERS reports
141
46 serious, 7 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SERIOUS CARDIOPULMONARY REACTIONS Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following perflutren-containing microsphere administration. Most serious reactions occur within 30 minutes of administration [see Warnings and Precautions (5.1) ]. Assess all patients for the presence of any condition that precludes OPTISON administration [see Contraindications (4) ]. Always have resuscitation equipment and trained personnel readily available [see Warnings and Precautions (5.1) ] . WARNING: SERIOUS CARDIOPULMONARY REACTIONS See full prescribing information for complete boxed warning. Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following perflutren-containing microsphere administration. Most serious reactions occur within 30 minutes of administration ( 5.1 ). Assess all patients for the...
What it is approved for
From the label in effect Dec 17, 2025.
OPTISON is indicated for use in adult and pediatric patients with suboptimal echocardiograms to opacify the left ventricle and to improve the delineation of the left ventricular endocardial borders. OPTISON is an ultrasound contrast agent indicated for use in adult and pediatric patients with suboptimal echocardiograms to opacify the left ventricle and to improve the delineation of the left ventricular endocardial borders ( 1 ).
Mechanism: The OPTISON microspheres create an echogenic contrast effect in the blood. The acoustic impedance of the OPTISON microspheres is much lower than that of the blood. Therefore, impinging ultrasound waves are scattered and reflected at the microsphere-blood interface and ultimately may be visualized in the ultrasound image. At the frequencies used in adult echocardiography (2 MHz to 5 MHz), the microspheres resonate which further increases the extent of ultrasound scattering and reflection.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 9, 2025 Supplement 25 · Efficacy LetterLabel
- Aug 17, 2012 Supplement 15 · Efficacy LabelLetter
- Dec 31, 1997 Original approval · Type 3 - New Dosage Form Other Important Information from FDA
1 products under this application
- OPTISON · ALBUMIN HUMAN 10MG/ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Albumin Human" as an intervention, any sponsor and status, largest first.
- Study to Investigate CSL112 in Subjects With Acute Coronary SyndromePivotal-lookingCompleted
CSL BehringIndustry
NCT03473223 · 18,226 participants · Start Mar 21, 2018 · Primary completion Feb 16, 2023
Drug: Apolipoprotein A-I [human] (apoA-I) · For: Acute Coronary Syndrome
Sites: Alexander City, Alabama; Birmingham, Alabama; Huntsville, Alabama · 903 sites in all
- Safety Study of ProQuad® rHA in Infants (V221-037)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT00560755 · 3,388 participants · Start Oct 24, 2007 · Primary completion Nov 24, 2008
Drug: ProQuad® · For: Measles; Mumps; Rubella and 1 more
- Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years OldPivotal-lookingCompleted
Shanghai Institute Of Biological ProductsIndustry
NCT05158777 · 2,480 participants · Start Feb 13, 2022 · Primary completion Nov 14, 2022
Drug: Live attenuated varicella vaccines manufactured by Shanghai Institute of Biological Products Co.,Ltd.; Live attenuated varicella vaccines manufactured by Changchun BCHT Biotechnology Co.,Ltd · For: Varicella
Sites: Zhenzhou, China
- Albumin and Crystalloid Administration in Septic ShockPivotal-lookingRecruiting
Asan Medical CenterAcademic, hospital or other
NCT05148286 · 2,426 participants (planned) · Start Jan 17, 2022 · Primary completion Sep 30, 2027
Drug: Treatment; Placebo · For: Septic Shock
Sites: Seoul, South Korea
- Intravenous Immune Globulin (IVIG) to Prevent Neonatal InfectionPivotal-lookingCompleted
NICHD Neonatal Research NetworkResearch network
NCT01203345 · 2,416 participants · Start Jan 1988 · Primary completion Mar 1991
Drug: IVIG; Placebo · For: Infant, Newborn; Infant, Low Birth Weight; Infant, Small for Gestational Age and 2 more
Sites: Birmingham, Alabama; Washington D.C., District of Columbia; Miami, Florida · 8 sites in all
- Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years OldPivotal-lookingStatus unknown
Sinovac (Dalian) Vaccine Technology Co., Ltd.Industry
NCT05015686 · 2,400 participants (planned) · Start Sep 30, 2021 · Primary completion Feb 9, 2022
Drug: Live attenuated varicella vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd; Live attenuated varicella vaccines manufactured by Changchun BCHT Biotechnology Co.,Ltd and 2 more · For: Varicella
Sites: Shangqiu, China
- Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT00566527 · 1,620 participants · Start Nov 29, 2007 · Primary completion Dec 29, 2008
Drug: ProQuad® manufactured with recombinant Human Albumin (rHA) · For: Measles; Mumps; Rubella and 1 more
- The Conservative vs. Liberal Approach to Fluid Therapy of Septic Shock in Intensive Care TrialPivotal-lookingCompleted
Anders Perner, MD, PhDAcademic, hospital or other
NCT03668236 · 1,554 participants · Start Nov 27, 2018 · Primary completion Feb 14, 2022
Drug: Isotonic crystalloids · For: Septic Shock
Sites: Brussels, Belgium; Pilsen, Czechia; Aalborg, Denmark · 31 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dizziness15
- back pain13
- chest pain12
- drug ineffective12
- no adverse event12
- nausea11
- dyspnoea9
- feeling hot7
- headache7
- flushing6
- off label use6
- product quality issue6
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 2 |
| 2006 | 1 |
| 2008 | 1 |
| 2010 | 2 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 14 |
| 2015 | 7 |
| 2016 | 10 |
| 2017 | 6 |
| 2018 | 11 |
| 2019 | 7 |
| 2020 | 2 |
| 2021 | 5 |
| 2022 | 11 |
| 2023 | 12 |
| 2024 | 15 |
| 2025 | 13 |
| 2026 | 20 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Intravenous Optison (FS069) enhances pulmonary vein flow velocity signals: a multicenter study.
Ellahham S, Hausnerova E, Gottdiener J · Clin Cardiol 2000 · Clinical Trial, Multicenter Study
- Reliability of semiquantitative ultrasonic perfusion imaging of the brain.
Eyding J, Wilkening W, Reckhardt M, et al. · J Neuroimaging 2004 · Clinical Trial, Comparative Study
- Effects of ultrasound contrast agents on Doppler tissue velocity estimation.
Ressner M, Brodin LA, Jansson T, et al. · J Am Soc Echocardiogr 2006 · Comparative Study, Controlled Clinical Trial
- Meta-analysis of contrast-enhanced ultrasound for the differentiation of benign and malignant breast lesions.
Hu Q, Wang XY, Zhu SY, et al. · Acta Radiol 2015 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Comparative Safety of Ultrasound Enhancing Agents: A Systematic Review and Bayesian Network Meta-Analysis.
Gonzalez RF, Cabra A, Liu D, et al. · Am J Cardiol 2025 · Systematic Review, Comparative Study
- Anti-carbamylated protein antibodies and skin involvement in patients with systemic sclerosis: An intriguing association.
Favoino E, Prete M, Vettori S, et al. · PLoS One 2018 · Clinical Trial, Research Support, Non-U.S. Gov't
Sponsor: Ge Healthcare
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.